AFYA stock forecast, quote, news & analysis

Key Takeaways

• Afya Limited (AFYA) shares declined roughly 16% over the last 30 days, from about $12.04 on September 28, 2026, to near $10.14 in late October.
• The drop was triggered primarily by Brazil's October 25 presidential runoff result, which sparked a broad selloff across Brazilian assets and weighed on U.S.-listed names with heavy Brazil exposure.
• The pending merger with Yduqs Participações S.A. (YDUQ3), which will delist Afya from Nasdaq and move trading solely to Brazil's B3 exchange, remains a central overhang on sentiment.
• Over the last quarter, the stock is down roughly 29% from the mid-teens, reflecting both merger-related repricing and macroeconomic and currency pressures.
• Fundamentals remain steady rather than rapid: first-half revenue rose 7% year over year, though margins narrowed, and the next earnings report is scheduled for November 12.
• Analyst views are mixed, with a consensus "Hold" rating and an average one-year price target of about $16.63.
• For deeper detail on valuation and guidance, explore Afya's Price Targets, Earnings, and Forecast pages.
• For data-driven trading ideas, explore Trending AI Robots.

Afya Limited (AFYA) Company Overview and Market Position

Afya Limited is a leading medical education group and medical practice solutions provider in Brazil. The company operates a network of medical schools, offers undergraduate and graduate health-science programs, and provides continuing education and digital solutions for healthcare professionals. Through its medical practice solutions segment, Afya supports physicians with tools and services beyond formal education.

Investors follow the stock for its exposure to Brazil's structural physician shortage, demographic trends supporting demand for medical education, and the company's ability to expand its approved medical seat capacity while generating healthy margins and cash flow. Afya has traded on Nasdaq since its 2019 direct listing, making it one of the more accessible ways for U.S. investors to gain exposure to Brazil's healthcare education sector.

Afya Limited (AFYA) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, AFYA fell approximately 16%, sliding from a closing price of $12.04 on September 28, 2026, to about $10.14 by late October. The move was not a straight line: shares rallied roughly 24% earlier in October as the market digested the proposed Yduqs merger, reaching the low-to-mid $15 range, before a single-session decline of roughly 29% on October 26 erased those gains.

The quarterly trend tells a similar story of elevated volatility and net weakness. From roughly $14.20 in late July 2026, the stock is down about 29%. The stock's 52-week range of roughly $10.05 to $16.16 underscores how the combination of the merger announcement, currency movements, and Brazil's political calendar has driven wide swings in the share price.

What Drove AFYA Stock Price in the Last 30 Days

The decisive catalyst was Brazil's October 25, 2026, presidential runoff. The victory by Luiz Inácio Lula da Silva, with roughly 51.8% of the vote against expectations that had favored his opponent, triggered a sharp repricing of Brazilian assets. The Brazilian real weakened against the dollar, and Brazil-focused equities, including AFYA, sold off as investors reassessed currency, interest-rate, and fiscal-policy risks under a new administration.

Compounding the move is the pending merger with Yduqs Participações S.A. Announced on September 23, 2026, the binding agreement will merge Afya into Yduqs, with the combined company listed exclusively on Brazil's B3 exchange under the Novo Mercado segment. Under the terms, each Afya share would be exchanged for 6.408347 newly issued Yduqs shares, leaving legacy Afya shareholders with about 69% of the combined group. Afya's Nasdaq-listed Class A shares would be delisted, and U.S. retail investors who do not qualify as institutional buyers may instead receive cash proceeds after their share consideration is sold on B3, introducing structural and timing uncertainty.

What Drove AFYA Stock Performance Over the Last Quarter

Across the broader quarter, two forces shaped the stock. First, the September merger announcement reframed the investment thesis, shifting attention from Afya's standalone growth story toward execution risk, delisting mechanics, and the integration of two major Brazilian education groups. Second, a difficult macro backdrop in Brazil — including a Selic policy rate near 14.00% and a weaker currency — has pressured margins and investor sentiment.

Fundamentals have remained relatively resilient. Half-year revenue grew 7% year over year, and the company maintained its 2026 adjusted EBITDA guidance of roughly BRL 1.7 billion to BRL 1.8 billion, but margins narrowed compared with the prior year, leaving less cushion to absorb currency and interest-rate shocks. These factors help explain why the stock has trended lower even as revenue continues to expand.

Trending AI Robots

Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, but only the top-performing and most relevant strategies appear in the curated Trending AI Robots section. These bots vary widely in strategy, timeframe, and performance metrics, ranging from short-term momentum signals to longer-horizon trend and pattern-based approaches, so investors can browse options that match different risk profiles and trading styles. The section is designed to help users quickly identify strategies that are currently generating attention based on their recent results. Exploring the page can provide a useful starting point for traders looking to complement their own research with systematic, data-driven tools.

AFYA Stock Forecast Drivers: What Investors Should Watch Next

Several factors will likely influence AFYA's trajectory in the coming months. The November 12 earnings report and any updates to full-year 2026 guidance are near-term focal points, particularly around margins, cash flow, and medical seat growth. Progress on the Yduqs merger — including shareholder votes, antitrust review by Brazil's CADE, and the timeline toward the March 31, 2028 long-stop date — will remain a key driver, as will the exchange-ratio mechanics and delisting logistics that affect U.S. holders.

At the macro level, investors will monitor the Brazilian real, the Selic interest-rate path, and fiscal-policy signals from the new administration, all of which directly affect a dollar-quoted stock that earns revenue in reais. Analyst expectations remain mixed, with a consensus "Hold" rating and an average price target around $16.63, reflecting genuine uncertainty about the merger's execution and Brazil's policy environment. These are factors to watch, not a basis for guaranteed outcomes.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations